Literature DB >> 25167928

Comparisons of Surgery and/or Chemotherapy in the Treatment of Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma.

Bo Wang1, Chengwei Zhang, Bin Wang, Lianbin Zhang.   

Abstract

BACKGROUND/AIMS: To investigate the clinical features, imaging characteristics, treatment, and prognosis of primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.
METHODS: We retrospectively analysed the clinical, imaging, and follow-up data of 13 patients (median age, 59 years; range, 21-67 years) with primary pulmonary MALT lymphoma.
RESULTS: The main clinical manifestations were chest discomfort (six patients), cough (two), fever (two), chest pain (one), and no obvious symptoms (two). Six patients underwent surgery; three had postoperative chemotherapy; four had chemotherapy alone; and three only had symptomatic and supportive treatment. The follow-up duration was one to 11 years, with one patient lost to follow-up. Two patients died (two years and 11 years post-diagnosis). As of this report, the remaining 10 patients were alive with no disease progression.
CONCLUSIONS: Pulmonary MALT lymphoma has atypical clinical manifestations and non-specific imaging changes, and the diagnosis depends on a pathological examination. For patients with confined lesions for which conventional biopsy cannot be performed, surgical excision plays an important role in clarifying the diagnosis and obtaining good therapeutic results and a good prognosis.

Entities:  

Mesh:

Year:  2014        PMID: 25167928      PMCID: PMC4990088          DOI: 10.5761/atcs.oa.14-00145

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  13 in total

1.  Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.

Authors:  R Borie; M Wislez; G Thabut; M Antoine; A Rabbat; L-J Couderc; I Monnet; H Nunes; F-X Blanc; H Mal; A Bergeron; D Dusser; D Israël-Biet; B Crestani; J Cadranel
Journal:  Eur Respir J       Date:  2009-06-18       Impact factor: 16.671

2.  [Clinical and imaging manifestations of pulmonary mucosa-associated lymphoid tissue lymphoma].

Authors:  Xin Sui; Wei Song; Zheng-Yu Jin; Rui-E Feng; Quan-Cai Cui; Hua-Dan Xue; Shuo Li; Hao Sun
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2012-02

3.  Role of surgery in the treatment of primary pulmonary B-cell lymphoma.

Authors:  Frederic Vanden Eynden; Elie Fadel; Marc de Perrot; Vincent de Montpreville; Sacha Mussot; Philippe Dartevelle
Journal:  Ann Thorac Surg       Date:  2007-01       Impact factor: 4.330

4.  Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.

Authors:  Claire W Michael; Patti H Richardson; Carole W Boudreaux
Journal:  Ann Diagn Pathol       Date:  2005-06       Impact factor: 2.090

Review 5.  Primary pulmonary non-Hodgkin's lymphoma: ten cases with a review of the literature.

Authors:  Celalettin İbrahim Kocatürk; Ekrem Cengiz Seyhan; Mehmet Zeki Günlüoğlu; Nur Urer; Kamil Kaynak; Seyyit İbrahim Dinçer; Mehmet Ali Bedirhan
Journal:  Tuberk Toraks       Date:  2012

6.  [Clinical characteristics and diagnosis of pulmonary mucosa-associated lymphoid tissue-derived (MALT) lymphoma: a retrospective analysis of 29 cases].

Authors:  Ai-wu Li; Jian-fang Xu; Cai-cun Zhou; Chun-yan Wu; Yan-li Wang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-05

7.  Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up.

Authors:  Marlene Troch; Berthold Streubel; Ventzislav Petkov; Karl Turetschek; Andreas Chott; Markus Raderer
Journal:  Anticancer Res       Date:  2007 Sep-Oct       Impact factor: 2.480

Review 8.  Primary pulmonary lymphoma.

Authors:  J Cadranel; M Wislez; M Antoine
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

9.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.

Authors:  Karin Ekström Smedby; Claire M Vajdic; Michael Falster; Eric A Engels; Otoniel Martínez-Maza; Jennifer Turner; Henrik Hjalgrim; Paolo Vineis; Adele Seniori Costantini; Paige M Bracci; Elizabeth A Holly; Eleanor Willett; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Nikolaus Becker; Silvia De Sanjosé; Brian C-H Chiu; Luigino Dal Maso; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Andrew E Grulich; Wendy Cozen
Journal:  Blood       Date:  2008-02-08       Impact factor: 22.113

10.  Chlamydiae and Mycoplasma infections in pulmonary MALT lymphoma.

Authors:  E Chanudet; P Adam; A G Nicholson; A C Wotherspoon; R Ranaldi; G Goteri; S A Pileri; H Ye; H K Müller-Hermelink; M-Q Du
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

View more
  2 in total

1.  Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study.

Authors:  Wei Yan; Bin Wu; Ai-Jun Liao; Wei Yang; Hui-Han Wang
Journal:  Ann Hematol       Date:  2021-01-22       Impact factor: 3.673

Review 2.  Nodular pulmonary amyloidosis and obvious ossification due to primary pulmonary MALT lymphoma with extensive plasmacytic differentiation: Report of a rare case and review of the literature.

Authors:  Hua Xiang; Zuqun Wu; Zhaoming Wang; Hongtian Yao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.